Erytropoietin behandling kan forbedre kognition ved neuropsykiatriske lidelser

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Erytropoietin behandling kan forbedre kognition ved neuropsykiatriske lidelser. / Kjær, Kristian Skov; Hageman, Ida; Wörtwein, Gitta; Jørgensen, Martin Balslev; Miskowiak, Kamilla Woznica.

In: Ugeskrift for Laeger, Vol. 179, No. 22, V01170037, 14.08.2017, p. 2-6.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kjær, KS, Hageman, I, Wörtwein, G, Jørgensen, MB & Miskowiak, KW 2017, 'Erytropoietin behandling kan forbedre kognition ved neuropsykiatriske lidelser', Ugeskrift for Laeger, vol. 179, no. 22, V01170037, pp. 2-6. <http://ugeskriftet.dk/videnskab/erytropoietinbehandling-kan-forbedre-kognition-ved-neuropsykiatriske-lidelser>

APA

Kjær, K. S., Hageman, I., Wörtwein, G., Jørgensen, M. B., & Miskowiak, K. W. (2017). Erytropoietin behandling kan forbedre kognition ved neuropsykiatriske lidelser. Ugeskrift for Laeger, 179(22), 2-6. [V01170037]. http://ugeskriftet.dk/videnskab/erytropoietinbehandling-kan-forbedre-kognition-ved-neuropsykiatriske-lidelser

Vancouver

Kjær KS, Hageman I, Wörtwein G, Jørgensen MB, Miskowiak KW. Erytropoietin behandling kan forbedre kognition ved neuropsykiatriske lidelser. Ugeskrift for Laeger. 2017 Aug 14;179(22):2-6. V01170037.

Author

Kjær, Kristian Skov ; Hageman, Ida ; Wörtwein, Gitta ; Jørgensen, Martin Balslev ; Miskowiak, Kamilla Woznica. / Erytropoietin behandling kan forbedre kognition ved neuropsykiatriske lidelser. In: Ugeskrift for Laeger. 2017 ; Vol. 179, No. 22. pp. 2-6.

Bibtex

@article{2b26f6d8d6dd44799b9bc88d0c57d3c0,
title = "Erytropoietin behandling kan forbedre kognition ved neuropsykiatriske lidelser",
abstract = "Cognitive dysfunction is a core feature in a range of neuropsychiatric disorders which reduces patients' workforce capacity - the largest socio-economic cost of these disorders. Nevertheless, there is no clinically available medical treatment with robust and enduring efficacy on cognitive deficits in most neuropsychiatric conditions. Recent research has shown that erythropoietin may have beneficial effects on cognitive dysfunction across neuropsychiatric disorders, including bipolar and unipolar disorders, schizophrenia, Parkinson's disease and multiple sclerosis.",
keywords = "English Abstract, Journal Article",
author = "Kj{\ae}r, {Kristian Skov} and Ida Hageman and Gitta W{\"o}rtwein and J{\o}rgensen, {Martin Balslev} and Miskowiak, {Kamilla Woznica}",
year = "2017",
month = aug,
day = "14",
language = "Dansk",
volume = "179",
pages = "2--6",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "22",

}

RIS

TY - JOUR

T1 - Erytropoietin behandling kan forbedre kognition ved neuropsykiatriske lidelser

AU - Kjær, Kristian Skov

AU - Hageman, Ida

AU - Wörtwein, Gitta

AU - Jørgensen, Martin Balslev

AU - Miskowiak, Kamilla Woznica

PY - 2017/8/14

Y1 - 2017/8/14

N2 - Cognitive dysfunction is a core feature in a range of neuropsychiatric disorders which reduces patients' workforce capacity - the largest socio-economic cost of these disorders. Nevertheless, there is no clinically available medical treatment with robust and enduring efficacy on cognitive deficits in most neuropsychiatric conditions. Recent research has shown that erythropoietin may have beneficial effects on cognitive dysfunction across neuropsychiatric disorders, including bipolar and unipolar disorders, schizophrenia, Parkinson's disease and multiple sclerosis.

AB - Cognitive dysfunction is a core feature in a range of neuropsychiatric disorders which reduces patients' workforce capacity - the largest socio-economic cost of these disorders. Nevertheless, there is no clinically available medical treatment with robust and enduring efficacy on cognitive deficits in most neuropsychiatric conditions. Recent research has shown that erythropoietin may have beneficial effects on cognitive dysfunction across neuropsychiatric disorders, including bipolar and unipolar disorders, schizophrenia, Parkinson's disease and multiple sclerosis.

KW - English Abstract

KW - Journal Article

M3 - Tidsskriftartikel

C2 - 28869012

VL - 179

SP - 2

EP - 6

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 22

M1 - V01170037

ER -

ID: 184209021